The role of healthy volunteers in clinical trials

Clinical trials are essential in bringing new drugs, treatments, and interventions to market. These trials progress through several phases, with each stage serving a specific purpose. In the early phases, particularly the first phase, healthy volunteers are often required. These individuals are generally healthy and do not have the disease or condition being studied, which allows researchers to establish a baseline for safety and determine the appropriate dosages for future stages of the trial.

Healthy volunteers may participate in clinical trials in different ways, such as through residential studies where they stay at the facility or by regularly visiting the facility while staying at home. The data collected during this initial phase provides researchers with a better understanding of how a drug interacts with the human body and what side effects, if any, might occur. This information is crucial before moving on to later phases, which involve participants who have the condition the drug is meant to treat.

Using healthy volunteers is critical in understanding a drug’s safety profile. While their participation helps gauge the interaction between the drug and the human body, it also ensures that any severe side effects are identified early on, before the drug is tested on those with the specific disease. At FluCamp, healthy volunteers are a key component of the research process. One participant, Jonathan, shared how his experience in a clinical trial contributed to potentially life-changing research.

The first phase of clinical trials typically involves healthy volunteers, focusing on safety, bodily effects, and dose determination. Once these factors are well-understood, researchers move to subsequent phases, which include participants with the disease the drug is intended to treat.

If you’re considering becoming a healthy volunteer, your eligibility will depend on various factors, such as age, gender, medical history, and fitness. Each clinical trial has its own criteria, and potential volunteers undergo a screening process, which includes tests like blood and urine analyses to ensure they are suitable candidates.

Safety in clinical trials is a common concern. Although healthy volunteers are among the first to test a new substance, rigorous review processes are in place to minimise risks. Researchers follow strict guidelines and regulations to ensure safety, and volunteers are fully informed about the trial and have the right to withdraw at any time. FluCamp participants have reported positive experiences, often with no significant symptoms.

Participating in a clinical trial as a healthy volunteer offers several benefits. Apart from contributing to medical advancements, volunteers are compensated for their time. FluCamp provides financial compensation, travel allowances, and amenities such as private rooms and en-suite bathrooms in residential programmes, ensuring volunteers’ comfort and support throughout the trial.

Healthy volunteers play a vital role in clinical trials by helping to establish the safety of a drug before it is tested on individuals with the targeted condition. Volunteers can feel secure knowing their participation is well-regulated and rewarded, making a meaningful contribution to medical research.

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    Versatile MDCK cells in research and biotechnology

    MDCK (Madin-Darby Canine Kidney) cells are an essential tool in biological and medical research, especially in virology, cell biology, and studies involving membrane transport. Originally derived in 1958 from the kidney of a healthy adult female

    hVIVO plc

    Exploring the human viral challenge model for influenza research

    This study evaluates the human viral challenge model using the A/Perth/16/2009 H3N2 influenza virus, involving 216 volunteers across five clinical studies. Administered intranasally under controlled conditions, the research aimed to improve the understanding of influenza infection

    hVIVO plc

    Advancing influenza research with new challenge agents

    Controlled Human Infection Studies (CHIS) have proven to be essential in exploring human responses to respiratory infections and testing the effectiveness of vaccines and treatments. These studies hinge on selecting an appropriate challenge virus, making a

    hVIVO plc

    hVIVO’s patient enrolment & retention at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Inside hVIVO’s cutting-edge QA facility at Canary Wharf

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Virus portfolio for RSV research and development

    Respiratory Syncytial Virus (RSV), discovered in 1956, is a common and contagious RNA virus responsible for a range of respiratory illnesses worldwide. Initially identified by Dr. Robert Chanock and colleagues in chimpanzees, RSV belongs to the

    hVIVO plc

    Clinical trial eligibility: Pre-screening and Screening

    In clinical trials, ensuring patient safety is paramount, and researchers must identify suitable participants who meet specific requirements. To this end, there are distinct processes involved, known as pre-screening and screening, which help determine whether a

    hVIVO plc

    Connecting Airway Epithelial Cell Models with Human Challenge Studies

    Airway epithelial cells cultured in Air–Liquid Interface (ALI) conditions provide an environment that closely resembles the human airway system. This method facilitates improved oxygen availability and supports cellular differentiation, replicating the physiological conditions of the human

    hVIVO plc

    Esmée shares her FluCamp clinical trial volunteer experience

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Overcoming challenges in high-growth regulated industries

    The Navigating Risk podcast recently explored the challenges faced by high-growth businesses operating in highly regulated industries, particularly life sciences. Helen Yates, the Editor of Global Thought Leadership, engaged in a conversation with Mo Khan, the

    hVIVO plc

    Take a 360° interactive tour of a FluCamp Volunteer Room

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Clinical trial approval process in the UK

    The process of obtaining approval for clinical trials is comprehensive, as it involves multiple regulatory bodies that ensure the safety and efficacy of the medical interventions being tested. Researchers begin by meticulously planning the trial, outlining

    hVIVO plc

    hVIVO reports positive results from RSV antiviral human challenge trial

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has noted the announcement by Enanta Pharmaceuticals, reporting positive topline results from

    hVIVO plc

    The importance of Clinical Trial Monitoring

    Monitoring is essential from the moment a clinical trial is planned until it concludes. This ensures that the study remains unbiased, patient safety is prioritised, and accurate results are achieved. The process of clinical trial monitoring